Feasibility of Day-surgery Management for Patients Undergoing Robotic Radical Prostatectomy: a Randomized Trial

Not Applicable

Active, not recruiting

• Conditions: Prostate Cancer

• Registration Number: NCT06891664
• Lead Sponsor: Regina Elena Cancer Institute

Brief Summary

To compare the day-surgery approach versus routine management in patients undergoing robotic radical prostatectomy, aimed at evaluating the feasibility of a one-day hospitalization regimen for robotic radical prostatectomy.

The study will allow to evaluate the patients'compliance and subsequently investigate the safety, the impact on the patient's quality of life and on the healthcare costs resulting from day-surgery management of patients undergoing robotic radical prostatectomy.

Detailed Description

The clinical study is aimed at evaluating the compliance of patients, candidates for robot-assisted radical prostatectomy for prostate cancer, to be enrolled in an RCT that provides for assignment to day surgery management (experimental arm) or ordinary management (control arm). The study involves the evaluation of the compliance of patients, candidates for robot-assisted radical prostatectomy for prostate cancer, to be enrolled in an RCT that provides for assignment to day surgery management (experimental arm) or ordinary management (control arm).

The study will allow us to test a protocol for day-surgery management that includes all the clinical and technological measures at our disposal, including single-port robotic surgery and telemedicine. Using the experience and results obtained from this trial, it will then be possible to design a confirmatory multicenter RCT that compares day-surgery management vs ordinary management. The latter will then have the task of demonstrating with a high level of evidence that robotic radical prostatectomy can be performed safely in day-surgery, guaranteeing economic advantages to the facility while also favoring a more rapid recovery of the patient. Considering that approximately 20,000 radical prostatectomies are performed every year in Italy, this paradigm shift could guarantee a significant economic advantage. A transition of this type requires robust scientific evidence in order to convince doctors, patients and health systems to rely on a more efficient health model based on better management of resources.

Study Timeline

• Study Start: 2024-10-23
• Status Verified: 2025-03
• Study First Submitted: 2025-03-17
• Study First Submitted QC: 2025-03-17
• Last Update Submitted: 2025-03-17
• Study First Posted: 2025-03-24
• Last Update Posted: 2025-03-24
• Primary Completion: 2027-05-23
• Study Completion: 2027-05-23

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: Male
• Target Recruitment: 90

Inclusion Criteria

• patients with localized prostate adenocarcinoma at low-intermediate risk (EAU Risk classification);
• patients aged >= 18 years;
• patients with an indication to undergo robotic radical prostatectomy without lymphadenectomy according to the EAU guidelines;
• patients who agree to undergo robotic radical prostatectomy without lymphadenectomy according to the EAU guidelines by signing a written informed consent;
• patients eligible for robotic radical prostatectomy without lymphadenectomy and in the absence of contraindications to undergo the procedure;
• patient's ability to understand and willingness to sign a written informed consent indicating that he has understood the purpose and methods of conducting the study and is interested in participating.;
• patients able to follow the indications specified in the study protocol;
• patients domiciled (even temporarily) < 150 km away from the institution where the procedure will be performed;
• patients domiciled (even temporarily) < 60 minutes by car from a reference Emergency and Acceptance Department (DEA).

Exclusion Criteria

• patients > 75 years of age;
• ASA > 2;
• second simultaneous surgery;
• prostate volume > 80 cc estimated on preoperative imaging (transrectal ultrasound or magnetic resonance imaging);
• patients receiving anticoagulants or oral antiplatelet drugs;
• other concomitant tumors undergoing treatment;
• previous pelvic radiotherapy;
• previous surgery for benign prostatic hypertrophy;
• patients lacking the digital literacy required to take advantage of telemedicine intervention;
• patients who cannot benefit from at least one caregiver;
• patients not suitable for a day-surgery approach based on the clinical evaluation of the operating surgeons and anesthetists.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Study enrollment rate among eligible patients.	30 months	RCT (randomized controlled trial) enrollment measured as the relative frequency percentage of patients who meet the eligibility criteria and agree to participate in the proposed trial (numerator), divided by the number of all eligible patients in the recruitment period (denominator). Patients who withdraw consent before knowing the outcome of randomization will be counted as having refused participation. The expected result is an enrollment rate of at least 30%. Therefore, the primary objective will be considered achieved if at least 30% of eligible patients agree to participate in the aforementioned trial

Secondary Outcome Measures

Name	Time	Method
Study Retention Rate	30 months	The retention rate will be measured as the relative percentage frequency of patients who remain in the study (numerator) of the total number of randomized patients (denominator). Patients who withdrew consent before knowing the outcome of randomization will be excluded from the denominator. In addition, the specific reasons for failure to remain will be listed. The retention rate will be compared between the two treatment arms.

Trial Locations

Locations (1)

"Regina Elena" National Cancer Institute; 🇮🇹 Rome, Italy